Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study.

[1]  R. Chaiwarith,et al.  Impact of the frequency of plasma HIV-1 RNA monitoring on the outcome of antiretroviral therapy. , 2011, Current HIV research.

[2]  E. Delaporte,et al.  Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. , 2011, The Lancet. Infectious diseases.

[3]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[4]  Richard D Moore,et al.  Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. , 2008, International journal of epidemiology.

[5]  James M Robins,et al.  The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals , 2010, AIDS.

[6]  J. Robins,et al.  When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study , 2016, Journal of acquired immune deficiency syndromes.

[7]  John W. Ward,et al.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  R. Haubrich,et al.  A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  D. Bereczki,et al.  The Cochrane Database of Systematic Reviews , 2003 .

[10]  D. Podzamczer,et al.  Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[12]  R B D'Agostino,et al.  Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. , 1990, Statistics in medicine.

[13]  C. Sabin,et al.  British HIV Association guidelines for the routine investigation and monitoring of adult HIV‐1‐infected individuals 2011 , 2012, HIV medicine.

[14]  James M. Robins,et al.  The International Journal of Biostatistics CAUSAL INFERENCE When to Start Treatment ? A Systematic Approach to the Comparison of Dynamic Regimes Using Observational Data , 2011 .

[15]  Richard Degerman,et al.  Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial , 2011, BMJ : British Medical Journal.

[16]  S. Weissman,et al.  Randomized Controlled Trial: 4 Month versus 6 Month Monitoring of HIV-infected Patients on Highly Active Antiretroviral Therapy , 2016, Journal of Community Health.

[17]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[18]  W. A. Thompson,et al.  On the treatment of grouped observations in life studies. , 1977, Biometrics.

[19]  Richard L. Degerman,et al.  CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study , 2011, BMJ : British Medical Journal.

[20]  A. Walker,et al.  Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial , 2013, The Lancet.

[21]  B. Gazzard,et al.  Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? , 2008, AIDS.

[22]  Donna Spiegelman,et al.  Easy SAS calculations for risk or prevalence ratios and differences. , 2005, American journal of epidemiology.

[23]  J. Robins,et al.  Comparison of dynamic treatment regimes via inverse probability weighting. , 2006, Basic & clinical pharmacology & toxicology.

[24]  P. Keiser,et al.  A Model for Reduced HIV-1 Viral Load Monitoring in Resource-Limited Settings , 2013, Journal of the International Association of Providers of AIDS Care.

[25]  L. Chang,et al.  Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. , 2010, The Cochrane database of systematic reviews.

[26]  Hollis G. Potter,et al.  Author Manuscript , 2013 .

[27]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[28]  James M Robins,et al.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. , 2016, American journal of epidemiology.

[29]  Arrow trial team.  Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial , 2013 .

[30]  A. Breckenridge,et al.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial , 2010, The Lancet.